Last updated: July 21, 2026
Isosulfan Blue is a dye product used in medical procedures for visualization and mapping. Public drug-development and FDA-accessible exclusivity records are not available in the provided source set, and no Orange Book patent listings or FDA approval history can be established here. As a result, a complete, data-backed investment scenario tied to patent life, exclusivity end dates, or generic/biosimilar entry risk cannot be produced from verified records.
Isosulfan Blue: What is the product’s regulatory status and is it FDA-approved?
Featured snippet: No verified FDA approval, NDA/BLA record, or Orange Book status can be confirmed from the information provided.
Isosulfan Blue is it an NDA, ANDA, or OTC/procedure dye
Isosulfan Blue is commonly described as a medical dye used during surgical procedures. Investment-grade fundamentals require confirmation of:
- FDA marketing category (NDA vs ANDA reference vs other marketing pathway)
- strength, dosage form, and labeled indication(s)
- current sponsor and label version
- distribution model (hospital supply vs wholesaler)
- safety labeling and Risk Evaluation and Mitigation Strategy (REMS) presence
None of these elements are validated in the provided source material.
What is the Orange Book status of Isosulfan Blue?
Featured snippet: Orange Book status cannot be determined from the provided data.
Without an Orange Book record, it is not possible to quantify:
- listed patents
- expiration dates by patent family
- exclusivity periods that constrain generic entry
- whether the product is already off-patent or facing Paragraph IV litigation risk
What patents protect Isosulfan Blue and how strong is the patent estate?
Featured snippet: Patent protection cannot be mapped from the provided information.
How many patents cover Isosulfan Blue (composition, formulation, methods)?
A rigorous patent estate review requires identification of:
- composition-of-matter patents for the dye or stabilized forms
- manufacturing process patents
- formulation patents (pH, stabilizers, solubilizers, osmolarity, sterile filtration/containment)
- method-of-use patents (injection volume, labeling sequence, imaging workflow, lymphatic mapping)
- device-adjacent patents if used with specific platforms
No patent numbers, assignees, jurisdictions, or expiration dates are provided, so strength scoring is not possible.
Which companies own Isosulfan Blue patents and filings?
Ownership and control are critical for licensing and litigation exposure. No assignees or filing entities are available here.
When does Isosulfan Blue lose exclusivity and what is the generic launch timeline risk?
Featured snippet: Exclusivity timeline cannot be established from the provided data.
FDA exclusivity vs patent expiration: which drives entry?
For investment planning, generic entry risk depends on whether exclusivity (5-year/3-year/7-year, orphan, pediatric, etc.) or patent expiration is the binding constraint. The necessary FDA exclusivity and patent expiry inputs are not present.
What generic entry risks exist for Isosulfan Blue?
A complete entry-risk view must cover:
- historical generic approvals and launch timing
- existing ANDAs and whether they are authorized generics
- supply concentration risk if the product is specialized
- substitution barriers at the hospital formulary level
No such competitive intelligence is supported by the provided information.
What patent litigation affects Isosulfan Blue and are Paragraph IV challenges pending?
Featured snippet: Patent litigation status cannot be verified from the provided information.
Paragraph IV challenges and settlements: what would matter for investors?
For high-confidence scenarios, one needs:
- listed Orange Book patents targeted in Paragraph IV filings
- court case numbers, venues, and scheduled trial dates
- 30-month stay status or resolved settlement terms
- design-around disclosures (if any)
No litigation records are available in the provided source set.
What formulations and dosing strengths are protected for Isosulfan Blue?
Featured snippet: Formulation and strength-specific protection cannot be mapped.
Injection strengths, vial sizes, and sterile manufacturing
Investment relevance depends on whether different strengths or packaging configurations have separate patent coverage. No strength-specific label or formulation patent mapping is available.
How does Isosulfan Blue compare with alternative visualization dyes for investment risk?
Featured snippet: Comparative market substitution cannot be quantified without verified labeled alternatives, pricing, and hospital usage patterns.
Direct substitutes that typically drive substitution
In clinical practice, visualization dyes may include indocyanine green, methylene blue, patent blue, and related agents depending on indication and workflow. To model investment risk, you need:
- labeled indication overlap
- compatibility with equipment
- safety profiles and contraindication patterns
- payer coverage and hospital procurement preferences
No market-access or label-overlap evidence is provided here.
Commercial fundamentals: what are the revenue drivers, margins, and supply-chain risks?
Featured snippet: Commercial fundamentals cannot be quantified from the provided information.
Revenue model for a dye product
Investors need unit economics:
- demand drivers tied to procedure volumes
- hospital formularies and purchasing cycles
- reimbursement dynamics by indication
- contract manufacturing supply constraints and lead times
- raw material and regulatory compliance costs
The provided prompt does not include sales, margin, channel, procurement, or reimbursement data.
Supply concentration and manufacturing/IP barriers
For sterile injectables and dyes, barriers often include:
- sterility assurance, filtration validation, and container-closure integrity
- batch-to-batch consistency under tight specifications
- dye impurity control and analytical method validation
- sourcing of starting materials
No manufacturer, site, or process constraint information is available here.
Investment scenario modeling for Isosulfan Blue: base, bull, bear cases
Featured snippet: Scenario ranges cannot be generated without verifiable regulatory, patent, and commercial inputs.
A credible model would require:
- patent/exclusivity end dates (or confirmation of off-patent status)
- FDA status and approval pathway
- evidence of generic competition or authorized supply
- price history and volume trends
- litigation or regulatory actions that affect launch
None of these inputs are supported by the provided information.
Key Takeaways
- Regulatory status: Cannot be confirmed as FDA-approved/NDA/BLA/Orange Book-listed from the provided data.
- Patent estate: Patent scope, assignees, and expiration dates cannot be mapped from the provided information.
- Exclusivity and generic risk: Exclusivity end dates and generic entry timelines cannot be established.
- Litigation: Paragraph IV and settlement risk cannot be verified.
- Commercial fundamentals: Revenue drivers, margins, and supply-chain exposure cannot be quantified.
FAQs
- How can investors assess Isosulfan Blue generic entry risk without Orange Book listings?
- What data points determine whether a dye product faces Paragraph IV litigation?
- Which manufacturing attributes most often drive regulatory delays for sterile injectable dyes?
- How do hospital formulary decisions change substitution risk between visualization dyes?
- What indicators best predict price erosion for specialized hospital dyes over a 3-to-5 year window?
References
No sources were provided in the prompt, so no citable references can be listed.
